Maya Reimbaeva

Ms. Maya Reimbaeva


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2025 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Open access
KAKathleen M. PhD Andersen
Kathleen M. PhD Andersen
TPThomas M. Mba Porter
Thomas M. Mba Porter
DFDeshayne B. PhD Fell
Deshayne B. PhD Fell
MRMaya Reimbaeva
Maya Reimbaeva
MMMary M. Moran
Mary M. Moran
SLSantiago M. C. Lopez
Santiago M. C. Lopez
Background: This study aimed to compare the clinical burden among young children hospitalized for respiratory syncytial virus (RSV) to coronavirus disease 2019 (COVID-19) or influenza. Methods: Patients <5 years of age hospitalized for RSV, COVID-19 or influenza between September 2022—August 2024 were selected from the PINC-AI Healthcare Database for retrospective cohort analysis. Hospitalization outcomes included length of stay, supplemental oxygen use, intensive care unit (ICU) admission, invasive mechanical ventilation (IMV) and inhospital death. Weighted robust Poisson regression models estimated risk ratios with 95% confidence intervals comparing RSV to COVID-19 and influenza, with further stratification by age at admission (<1, 1 and 2–4 years). Results: Among 56,634 children (43,766 RSV; 6,697 COVID-19; 6,171 influenza) hospitalized for the acute respiratory infections, children hospitalized for RSV were mean age 0.7 years, versus 0.7 (COVID-19) and 1.7 years (influenza), more often admitted to the ICU (28.2%, vs. 22.4% and 21.7%), required supplemental oxygen (46.1%, vs. 20.2% and 26.2%) and IMV (12.0%, vs. 8.3% and 8.2%). In adjusted regression models, increased risks of supplemental oxygen, ICU admission and IMV persisted with RSV as compared with COVID-19 and influenza. Risks with RSV were highest among children <1 year old. Inpatient mortality was observed [0.1% (RSV), 0.3% (COVID-19), 0.4% (influenza)]. Conclusion: Viral respiratory diseases cause a significant burden of illness in hospitalized children <5 years of age. Compared with COVID-19 and influenza, RSV had a significantly higher risk of nearly all inhospital outcomes examined. Inhospital mortality for COVID-19 and influenza was higher than RSV.

31 January 2022 in Journal of Public Health Research
Verified
Journal Article
Open access
PDF file
JNJennifer L. Nguyen
Jennifer L. Nguyen
MBMichael Benigno
Michael Benigno
DMDeepa Malhotra
Deepa Malhotra
MRMaya Reimbaeva
Maya Reimbaeva
ZSZiphora Sam
Ziphora Sam
BEBirol Emir
Birol Emir
Background: The United States has experienced high COVID- 19 case counts, hospitalizations, and death rates. This retrospective analysis reports changing trends in the demographics and clinical outcomes of hospitalized US COVID-19 patients between April and August 2020. Design and methods: The Premier Healthcare Database Special Release was used to examine patient demographics of hospitalized COVID-19 patients from all US Census Bureau divisions. Demographics included age, sex, race, and ethnicity. Clinical outcomes included in-hospital mortality, intensive care unit (ICU) admission, and receipt of invasive mechanical ventilation. Results: Overall, 146,491 hospitalized COVID-19 patients were included (mean [SD] age, 61.0 [18.4] years; 51.7% male; 29.6% White non-Hispanic). Monthly total hospitalizations decreased from 44,854 in April to 18,533 in August; ICU admissions increased from 19.8% to 23.6%, and ventilator use and inpatient mortality decreased from 18.6% to 14.5% and 21.0% to 11.4%, respectively. Inpatient mortality was highest in the Middle Atlantic division (20.3%), followed by the New England (19.0%), East North Central (14.2%), and Mountain (13.7%) divisions. Black non-Hispanic patients were overrepresented among hospitalizations (19.0%); this group comprises 12.2% of the US population. Patients aged <65 years made up 53% of hospitalizations and had lower inpatient mortality than those aged ≥65 years. Conclusions: Hospitalizations, ventilator use, and mortality decreased, while ICU admission rates increased from April to August 2020. Older individuals and Black non-Hispanics were found to be at elevated risk of severe outcomes. These trends could inform ongoing patient care and US public health policies to limit the further spread of SARS-CoV-2.

14 November 2024 in COVID
Verified
Journal Article
Open access
PDF file
ASAmie Scott
Amie Scott
JAJoanna Atkinson
Joanna Atkinson
WAWajeeha Ansari
Wajeeha Ansari
MRMaya Reimbaeva
Maya Reimbaeva
RSRichard H. Stanford
Richard H. Stanford
FDFlorin Draica
Florin Draica
A list of diagnosis codes mapped to CDC-defined high-risk conditions for severe COVID-19 outcomes is currently not available in the literature. We reviewed the CDC list of underlying conditions associated with severe COVID-19 and a coding expert and two clinicians mapped the relevant high-risk conditions to the appropriate ICD-10-CM codes. We additionally assessed the prevalence of these conditions in the Optum de-identified-Clinformatics® Data Mart Database and the Optum de-identified Electronic Health Record dataset. A comprehensive list of approximately 8200 codes were mapped to the CDC-defined high-risk underlying conditions; these ICD-10-CM codes were stratified into three groups corresponding with the CDC strength of evidence category (conclusive, suggestive, or mixed evidence). Applying these codes to administrative claims and EHR datasets demonstrated a consistent prevalence of high-risk conditions over four years (2018–2021). These findings present a comprehensive list of codes that can be used by clinicians and researchers to identify and characterize patients at high risk for severe COVID-19 outcomes.